Rite Aid reinstated with a Sell at Goldman Sachs. Goldman Sachs analyst Robert Jones reinstated Rite Aid (RAD) with a Sell and $1 price target following the merger termination with Albertsons. Jones said the now standalone company lacks necessary scale to effectively compete and negotiate with healthcare supply chain players.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.